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Right-Sided Infective Endocarditis 




Right-sided infective endocarditis is due to intravenous drug abuse. Right-sided 
infective endocarditis is rare. It comprises 5–10% of infective endocarditis cases. 
Traditionally, it has been reported more commonly in patients with medical devices 
such as pacemakers and defibrillators and dialysis catheters. Recently, there has 
been increase in right-sided infective endocarditis related to intravenous drug 
abuse. Right-sided infective endocarditis related to drug abuse mostly affects the 
tricuspid valve and rarely the pulmonary valve. Although, most uncomplicated 
cases do well with medical treatment, it is associated with considerable morbidity 
and mortality due to recurrent infection. Surgery for right-sided infective endocar-
ditis is uncommon especially in resource limited setting. Few current studies have 
explored surgical options in this group of patients. This chapter will review current 
literature related to right-sided infective endocarditis due to intravenous drug 
abuse.
Keywords: infective endocarditis, intravenous drug abuse
1. Introduction
Infective endocarditis (IE) is characterised by a microbial infection that involves 
the endocardial surface of the heart; it most often denotes infection of the heart 
valves or an intracardiac device [1]. Less commonly it involves septal defects, mural 
endocardium and the subvalvular apparatus [2]. The classic lesion is a vegetation, 
which is composed of platelets, fibrin enmeshed with microorganisms and inflam-
matory cells [3]. Infective endocarditis is caused by many different species of 
bacteria such as staphylococci, streptococci, enterococci and slow-growing Gram-
negative coccobacilli.
In the 1950s IE secondary to intravenous drug use was first described [4]. Right-
sided infective endocarditis (RSIE) secondary to intravenous drug use is a distinct 
entity and will be reviewed in this chapter.
2. Epidemiology
Intravenous drug abuse (IVDA) is a recognised risk factor for IE. Intravenous 
drug users are at a seven times higher risk for infective endocarditis compared to 
patients with rheumatic heart disease or prosthetic valves [3].
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Over the last decade there has been a steady increase in number of cases related 
to IE due to intravenous drug use. Between 2000 and 2008 the rate of IE due to 
IVDA has increased from 6 to 8% hospitalisation to 12% in the year 2013. During 
this period there has been an increase in IVDA related IE cases amongst younger 
white population. A similar distribution was noted between males and females [5].
In United States, North Carolina, a study reported a 12-fold increase in hospitali-
sations for intravenous drug use related IE over the last decade [6].
In the past IE related to IVDA was predominantly disease of men. A recent study 
has shown that there is a general increase in the rate of IVDA associated IE in the 
United States, with a relatively higher proportion of women compared to previous 
studies [5, 6]. In a recent South African Study, Meel et al. reported an increase in the 
incidence of IE related to IVDA amongst Africans. These were predominantly male 
and majority were HIV infected [7].
Infective endocarditis involving the right side accounts for 5–10% of cases of 
IE [8, 9].
RSIE may occur in patients with intracardiac devices but in intravenous drug 
users it is usually associated with HIV infection [9].
HIV infection in intravenous drug users is associated with a higher rate of IE 
compared to HIV uninfected users [10, 11]. Further, immunosuppression with lower 
CD4 count is associated with a higher predisposition to IE [9].
Intravenous drug use related IE involves the tricuspid valve in 46–78% of the 
cases, mitral valve in 24–32% of cases and the aortic valve in 8–19%. About 16% of 
the patients have multiple valve involvement. In the majority the infection occurs 
on the native valves. Intravenous drug use is characterised by recurrent infective 
endocarditis of the native valves [3].
3. Etiopathogenesis
The most common organism isolated in IVDA related IE is Staphylococcus aureus. 
It accounts for greater than 50% of the organisms cultured [3]. It tends to com-
monly infect the native tricuspid valve. In contrast streptococci and enterococci 
infect damaged valves, mostly aortic and the mitral valve. Other organisms include 
fungi, Pseudomonas aeruginosa and Gram-negative bacilli. Injection of contaminated 
material predisposes drug addicts to less commonly encountered organisms such as 
Corynebacterium species, Lactobacillus, Neisseria species and Bacillus cereus. In 3–5% 
of cases Polymicrobial infection is present [3].
The tricuspid valve is the most commonly involved valve in RSIE due to 
IVDA. Injection of recreational drugs results in entry of particulate matter such as 
talc into the circulatory system resulting in structural damage to the endothelium 
of the valve [12, 13]. Similarly, the left-sided valves get damaged by particulate 
matter that is less than 10 mm in size and is able to cross the pulmonary circulation 
[14]. The use of cocaine is associated with greater frequency of IE in IVDA. The 
possible mechanisms postulated include the ability of cocaine to cause vasospasm 
and tissue damage to the myocardium. It is also procoagulant and thus can cause 
thrombus formation and thus producing a nidus for bacterial seeding the damaged 
valve tissue [8]. Further, it has been postulated that intravenous drugs can result in 
pulmonary hypertension leading to increased turbulent blood flow across the valve 
resulting in endothelial damage to the right-sided heart valves.
The pathogenesis of formation of vegetation is complex. It involves interaction 
between the host, the organism, the endothelium, hemostatic pathways, the ability 
of the hosts immune system to eliminate the organism and the virulence of the 
specific microorganism [3].
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The microorganism once in the blood stream tend to attach themselves to the 
valve surface and proliferate at sites of endothelial damage resulting in further 
damage to the valve tissue. The microorganisms initially attach to the platelet-
fibrin nidus and then proliferate [15]. Microbial growth results in activation of the 
extrinsic coagulation pathway, monocytes release a myriad of pro-inflammatory 
cytokines and there is increased expression of fibronectin on the surface of the 
endothelial cells with resultant formation of a vegetation.
The vegetation grows further, with subsequent embolization and continued 
bacteraemia, if the host is unable to contain the infection [16].
4. Clinical features
Right-sided infective endocarditis usually presents with fever, persistent bacter-
aemia and septic emboli to the lungs. Initial presentation may comprise haemopty-
sis, cough or chest pain. Peripheral embolization must alert one to the presence of 
concomitant left-sided endocarditis or a shunt. Right heart failure is a result of both 
pressure and volume overload from pulmonary hypertension or organic tricuspid 
regurgitation or rarely obstruction of the tricuspid orifice by a vegetation [17, 18].
Pulmonary septic emboli may be complicated by pulmonary infarction, abscess, 
pneumothorax, and purulent pulmonary effusion [17] (Figures 1 and 2).
It is important to note that patients with RSIE do not always have an audible 
murmur of tricuspid regurgitation [13]. Other features unique to this group of 
patients with IE are the presence of co-infections with HIV, hepatitis C and hepatitis 
B infections, which complicate their clinical management and adversely affect their 
outcomes. A high degree of suspicion of IE must be maintained in IVDA as their 
clinical assessment can be quite challenging, especially in those who do not manifest 
the classic clinical features.
Additionally, the sensitivity and specificity of the modified Duke’s criteria in 
right-sided endocarditis has not been studied. Inclusion of septic pulmonary infarcts 
as a minor criteria in the modified Duke’s criteria may therefore be inappropriate [19].
Figure 1. 
An anterior-posterior chest X-ray showing increased cardiothoracic index with areas of alveolar opacification 




Colour Doppler ultrasound showing severe tricuspid regurgitation.
5. Diagnosis
In addition to the above mentioned clinical features and positive blood cultures, 
transthoracic echocardiography (TTE) greatly aids in establishing a diagnosis of IE, 
Figure 2. 
Multiple areas of consolidation suggestive of infarction and dilated right heart chambers on a CT scan of the 
chest of a patient with history of right-sided infective endocarditis due to intravenous drug abuse.
Figure 3. 
Modified apical four-chamber view showing multiple vegetations on the tricuspid valve (arrow) with a dilated 
right atrium and right ventricle.
5Right-Sided Infective Endocarditis Secondary to Intravenous Drug Abuse
DOI: http://dx.doi.org/10.5772/intechopen.84319
especially in cases with equivocal clinical presentation. TTE allows easy visualisa-
tion of vegetations on the anteriorly located tricuspid valve and associated tricuspid 
regurgitation (Figures 3 and 4) [20, 21].
A transesophageal echocardiography may be required in detection of vegetations 
on the pulmonary valve and for exclusion of left-sided valve involvement [22]. The 
Eustachian valve must be screened for presence of vegetations.
6. Management
The initial antimicrobial therapy should take into account four factors: (1) 
suspected organism (2) type of drug (3) the solvent used by the addict and (4) the 
location of Infection [17].
Empirical therapy in acute severely ill patients must consist of ampicillin and 
cloxacillin with gentamycin or vancomycin with gentamycin (in patients allergic to 
penicillin) [17]. Staphylococcus aureus must always be covered. Anti-pseudomonas 
agent must be added in a pentazocine drug addict. If an IVDA gives a history of 
brown heroin use mixed with lemon juice then an anti-fungal agent must be added 
due to a high risk of candida septicaemia. Anti-microbial therapy can be de-esca-
lated once the specific causative organism is isolated on blood cultures.
Due to reluctance of IVDA for prolonged hospital admission and the concerns 
related to their discharge on intravenous antibiotic therapy, a few studies have studied 
the possibility of treating IE in these patients with short course antibiotic therapy [23].
A 2 week treatment regimen has been advocated in non-complicated isolated 
tricuspid valve endocarditis. These patients must have low risk features such as 
good response to therapy, methicillin sensitive Staphylococcus aureus, small vegeta-
tion size (less than 20 mm), no features of peripheral embolization, absence of 
metastatic infection, lack of involvement of left-sided valves or prosthetic valve and 
absence of a severely immunosuppressed state. In such cases, a short 2 week course 
of intravenous cloxacillin or oxacillin alone may be used [24]. These patients must 
be closely followed up and the response to therapy must be assessed.
In complicated cases a 4–6 week course of intravenous therapy must be utilised. 
These include situations where there is poor response to antibiotic therapy, large 
vegetation size (>20 mm), septic emboli, use of penicillinase non-resistant antibiot-
ics, and a severely immunosuppressed state such as HIV with a CD4 count less than 
200cell/ml and associated involvement of left-sided valves [25–27].
Due to a high rate of recurrent IE in IVDA, surgery should only be considered in 
the following situations: (1) intractable right-sided heart failure with poor response 
to diuretics; (2) persistent bacteraemia despite use of appropriate antimicrobial 
therapy; and (3) large vegetation size of greater than 20 mm that do not diminish in 
size after repeated episodes of pulmonary emboli [25, 28, 29].
In general the outcomes of patients with IVDA related IE have been poor post 
surgery. A substantially high long term mortality has been reported for IE related 
surgery in IVDA compared to non-drug users [30–32].
In HIV-infected IVDAs with IE cardiac surgery does not worsen the outcome 
of either the IE or the HIV [17]. Patients with advanced HIV infection with severe 
immunosuppression. However, valve replacement surgery may have unacceptably 
high risks in selected patients with advanced HIV infection, low CD4 counts, and 
either a history of failed antiretroviral therapy or ongoing drug abuse that precludes 
therapy with antiretroviral agents [33].
The most commonly performed surgery for tricuspid valve endocarditis includes 
valvectomy, valve replacement or repair [34]. Valve repair is advocated by some 
studies but repair has not proven to be superior to either valve replacement or 
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valvectomy. In a few cases of RSIE valvectomy may be performed initially followed 
by subsequent bioprosthetic valve replacement once the infection has subsided 
and drug use discontinued. Pulmonary valve rarely requires replacement except in 
extreme cases of valve destruction. In cases where pulmonary valve replacement is 
deemed suitable, a homograft is preferred.
7. Prognosis
Overall, IVDA with RSIE have a lower mortality than those with left-sided 
infective endocarditis [14, 24, 35–39]. In one study the mortality was noted to be 
6% [40]. Factors associated with high mortality included a large vegetation size 
(>20 mm) and a fungal aetiology [41, 42].
In general patients with HIV do not have a poor outcome, except those with 
CD4 count <200 cells/ml. The major reason for repeat hospitalisation and recurrent 
endocarditis in IVDA is related to persistent use of drugs [30, 43, 44].
Finally, management of RSIE related to IVDA poses some ethical dilemmas. From 
the limited available literature, surgery should be offered for patients with surgical 
indications, with a first episode of IE in IVDAs, who are willing to undergo rehabili-
tation. If the patient presents with a second episode of IE due to recurrent IVDA, 
the decision to re-operate the patient, if indicated, is complex. It should be indi-
vidualised and discussed by the endocarditis team. It is reasonable to decline further 
surgical intervention in this group, especially in resource-limited settings [45].
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